Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab) Cambridge, UK – 10 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral ...
Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy ...
Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...
Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...
The Enterprise Investment Scheme Association's new report, in partnership with Beauhurst, looks into the impact of the ...
Headline inflation has fallen into the Reserve Bank's 2 to 3 per cent target for the first time in three years. Here's why it won't mean an early rate cut.
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement ...
Microbiotica is a spin-out from the not-for-profit Wellcome Trust Sanger Institute (pictured) which specialises in genome sequencing and has been researching the microbiome since 2010. The UK ...
CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback